Kaleido Biosciences, Inc. (KLDO)
0.0001
0.00 (0.00%)
USD |
OTCM |
Sep 09, 16:00
Kaleido Biosciences Debt to Equity Ratio
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| December 31, 2021 | 2.045 |
| September 30, 2021 | 0.7368 |
| June 30, 2021 | 0.4246 |
| March 31, 2021 | 0.2953 |
| December 31, 2020 | 1.025 |
| September 30, 2020 | 0.5802 |
| June 30, 2020 | 0.4029 |
| March 31, 2020 | 0.613 |
| Date | Value |
|---|---|
| December 31, 2019 | 0.4186 |
| September 30, 2019 | 0.2272 |
| June 30, 2019 | 0.1777 |
| March 31, 2019 | 0.1431 |
| December 31, 2018 | 0.2729 |
| September 30, 2018 | 0.2142 |
| December 31, 2017 | 1.999 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Cocrystal Pharma, Inc. | 1.284 |
| CNBX Pharmaceuticals, Inc. | -0.4388 |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | 0.0146 |
| Fulcrum Therapeutics, Inc. | 0.017 |